In the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) trial, SCD patients in the voxelotor arms had a reduction in hemolysis, with the consequence of increases in Hb concentrations, compared to the placebo group [9]. This evidence concerns the gene GSTM1 and Schnyder corneal dystrophy.